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HIV-2 GH-1 is a molecular clone derived from an AIDS patient from Ghana. In contrast to the prototypic molecular clone
ROD, GH-1 exhibits a narrow range of target cell specificity. By an infectious assay using HeLa-CD4 cells stably transfected
with an HIV-1 LTR-b-galactosidase reporter gene and transiently expressing various cloned chemokine receptors, we have
examined the coreceptor usage of GH-1. In contrast to ROD, which uses principally CXCR4, GH-1 was found to use mainly
if not exclusively CCR5 but not CXCR4. The distinct coreceptor usage of these two molecular clones allowed us to further
map the region of gp120 that is important for the coreceptor specificity. By constructing a series of chimeric viruses between
GH-1 and ROD, we have demonstrated that the C-terminal half of the V3 loop region of gp120 determines the differential
coreceptor usage between GH-1 and ROD, and only a few amino acid differences in this region appear to be able to shift the
specificity between CCR5 and CXCR4. Notably, the shift in the coreceptor usage from CCR5 to CXCR4 is associated with an
increase in the net positive charge in the V3 region. © 1999 Academic Press
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Since the discovery of the chemokine receptors CCR5
nd CXCR4 as the major entry coreceptors for macro-
hage-tropic (M-tropic or R5) and T-cell-line tropic (T-
ropic or X4) strains of HIV-1, respectively, the list of the
hemokine receptors capable of functioning as entry
oreceptors for different strains of HIV-1 is rapidly ex-
anding (Cairns and D’Souza, 1998). Recently, several
eports have been published on the coreceptor usage of
IV-2 and SIV (Endres et al., 1996; Bron et al., 1997; Chen
t al., 1997; Marcon et al., 1997; Reeves et al., 1997; Sol
t al., 1997; McKnight et al., 1998). While genetically
ivergent SIV strains all use CCR5 and not CXCR4 for
ntry coreceptor (Chen et al., 1997), a broad range of
hemokine receptors has been shown to be used as
oreceptor for HIV-2. CD4-independent infection by sev-
ral HIV-2 strains was shown to be directly mediated by
XCR4 (Endres et al., 1996; Reeves et al., 1997). HIV-2
OD/A (the prototype) and ROD/B (CD4-independent
ariant) also were able to use CCR3 and V28/CX3CR1
fficiently when facilitated by soluble CD4 (Reeves et al.,
997). When studied in a cell-to-cell fusion assay, the
nvelope protein of HIV-2 ROD was further found to be
apable of using CCR1, CCR2, CCR3, CCR4, CCR5,
XCR2, and CXCR4 (Bron et al., 1997). Primary HIV-2
solates also were shown to infect cells coexpressing
1 To whom reprint requests should be addressed. Fax: 181-6-6382-
i598. E-mail: akihiko.sato@shionogi.co.jp.
237D4 and either CCR5, CCR3 or CXCR4 (Sol et al., 1997).
ost HIV-2 strains that used CCR5 also could use CCR3.
s observed for HIV-1, HIV-2 strains derived from asymp-
omatic individuals generally use CCR5 or CCR3,
hereas those derived from AIDS patients often use
XCR4 (Sol et al., 1997). Recently the list of chemokine
eceptors that could be used by primary isolates of HIV-2
ere further expanded to include CCR1, CCR2b, CCR3,
CR4, and CXCR4 (McKnight et al., 1998). Some HIV-2
trains also were able to use orphan 7-transmembrane
-protein-coupled receptors STRL33/Bob and GPR15/
onzo, which were initially identified as entry corecep-
ors for some SIV strains (Deng et al., 1997). Thus the
oreceptor usage of HIV-2 appears to be much more
romiscuous than those of HIV-1 and SIV.
The cell tropism of HIV-1 is mainly determined by the
3 loop region of the envelope protein gp120 and amino
cid changes in the V3 loop affect the coreceptor usage
Choe et al., 1996; Cocchi et al., 1996; Bieniasz et al.,
997). The role of V3 loop of HIV-2 in the coreceptor
sage, however, remains to be seen. In this report, we
ave demonstrated that HIV-2 GH-1 strain derived from
n AIDS patient in Ghana (Hasegawa et al., 1989) mainly
f not exclusively uses CCR5 for virus entry in contrast to
IV-2 ROD (Clavel et al., 1986) that principally uses
XCR4. The distinct coreceptor usage of these two HIV-2
olecular clones has allowed us to map the regions of
p120 that determine the coreceptor usage of HIV-2. We
ave shown that, like HIV-1, the V3 loop region of gp120s critically important for the coreceptor usage of HIV-2
0042-6822/99 $30.00
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238 ISAKA ET AL.nd only a few amino acid differences especially in the
-terminal half of the V3 loop region correlate the shift of
oreceptor usage between GH-1 and ROD.
RESULTS AND DISCUSSION
HIV-2 ROD, a molecularly cloned and T-cell-line-
dapted HIV-2 strain (Clavel et al., 1986), was shown to
se CXCR4 as an entry coreceptor in cell-free virus
nfection assays (Endres et al., 1996; Reeves et al., 1997).
urthermore HIV-2 ROD was able to use CCR3 and V28/
X3CR1 when infection was facilitated by soluble CD4
Reeves et al., 1997). Another molecular clone HIV-2
H-1 (Hasegawa et al., 1989) shows ;85% homology
ith HIV-2 ROD in the nucleotide sequence but seems to
ave a narrower target cell specificity than ROD
Kawamura et al., 1998). Availability of a molecular clone
ith a coreceptor usage different from ROD would be
seful to map the region of gp120 involved in the core-
eptor usage of HIV-2. We therefore compared the infec-
ivity of ROD and GH-1 by using human T cell lines. As
hown in Fig. 1, ROD grew well in both Molt-4 and Jurkat,
hereas GH-1 grew only in Molt-4. Thus the infectivity of
IV-2 GH-1 is more restricted than that of HIV-2 ROD,
uggesting the difference in their coreceptor usage. Fur-
hermore infection of GH-1 to Molt-4 was found to be
ignificantly suppressed by RANTES but not by SDF-1,
hereas infection of ROD to Jurkat was suppressed by
DF-1 (data not shown, but see Fig. 6).
We therefore examined the coreceptor usage of HIV-2
H-1 by a cell-free infection assay using HeLa-CD4 cells
tably transfected with an LTR-b-gal reporter gene
FIG. 1. Growth of HIV-2 GH-1 and ROD in human T cell lines. Molt-4
nd Jurkat were infected with GH-1 and ROD. RT activity in culture
upernatants was determined at indicated time points postinfection. All
ssays were done in triplicate and mean 6 SD was obtained. Repre-
entative results from two separate experiments are shown.Tachibana et al., 1997). Parental HeLa-CD4 cells or ahose transiently transfected with one of the following
hemokine receptors, CCR1, CCR2b, CCR3, and CCR5,
ere infected with GH-1 and ROD as well as control X4
nd R5 HIV-1 strains. Viral infection was measured by
at-induced transactivation of b-gal. As shown in Fig. 2,
IV-2 GH-1 as well as R5 type HIV-1 NL162 (Tachibana et
l., 1997) infected only HeLa-CD4 expressing CCR5. On
he other hand, HIV-2 ROD and X4 type HIV-1 NL432
Adachi et al., 1986) were capable of infecting even
arental HeLa-CD4 cells apparently by using the endog-
nous CXCR4 (Endres et al., 1996; Reeves et al., 1997).
his was supported by inhibition with IVR7, a monoclonal
ntibody to CXCR4 (Hori et al., 1998). As shown in Fig. 3,
nfection of ROD as well as that of X4 type HIV-1 NL432
o HeLa-CD4 or HeLa-CD4 expressing CCR5 was effec-
ively blocked by IVR7. On the other hand, infection of
H-1 as well as that of R5 type HIV-1 NL162 to HeLa-CD4
xpressing CCR5 was not affected by IVR7 at all. Thus
H-1 uses mainly if not exclusively CCR5 but not CXCR4,
hereas ROD efficiently uses CXCR4 as reported previ-
usly (Endres et al., 1996; Reeves et al., 1997).
The distinct coreceptor usage of GH-1 and ROD with
FIG. 2. Coreceptor usage of HIV-2 GH-1. HeLa-CD4 cells stably
ransformed with LTR-b-gal were transiently transfected with an ex-
ression vector without or with the indicated chemokine receptors.
ells were infected with HIV-2 ROD, HIV-2 GH-1, HIV-1 NL432 (X4), and
IV-1 NL162 (R5). After 4 days, transactivation of the LTR-b-gal reporter
ene was measured. All assays were done in triplicate and mean 6 SD
as obtained. Representative results from three separate experiments
re shown.
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239ROLE OF V3 LOOP IN CORECEPTOR USAGE OF HIV-2egard to CCR5 and CXCR4 allowed us to map the critical
egions of gp120 in HIV-2 that determine the coreceptor
electivity for CCR5 and CXCR4. We therefore generated
series of gp120 chimeric viruses between GH-1 and
OD in the background of GH-1 (Fig. 4) and tested their
nfectivity to HeLa-CD4 or HeLa-CD4 transiently express-
ng CCR5. As shown in Fig. 5, GH-1(RODNN) in which the
FIG. 3. Distinct coreceptor usage between HIV-2 ROD and GH-1.
eLa-CD4 cells stably transformed with LTR-b-gal were transiently
ransfected with a control or a CCR5-expression vector and infected
ith indicated viruses. The treatment of cells with IVR-7, an monoclonal
nti-CXCR4 (Hori et al., 1998), or control mouse IgG was carried out for
h before infection. After 4 days, transactivation of the LTR-b-gal
eporter gene was measured. All assays were done in triplicate and
ean 6 SD was obtained. Representative results from three separate
xperiments are shown.
FIG. 4. Schematic depiction of the chimeric viruses between GH-1
nd ROD. Open and closed boxes indicate sequences derived fromtH-1 and ROD, respectively.ntire gp120 was derived from ROD was capable of
nfecting parental HeLa-CD4. Similarly, GH-1(RODNA) in
hich the N-terminal half of gp120 including the V3 loop
egion was derived from ROD-infected parental HeLa-
D4. The infection of these chimeric viruses was effec-
ively blocked by IVR7, a monoclonal antibody to CXCR4
Hori et al., 1998). In contrast, GH-1(RODAN) in which the
-terminal half of gp120 including the V3 loop region was
erived from GH-1 infected only CCR5-expressing HeLa-
D4 and was not affected by IVR7. The critical role of the
3 loop region in the coreceptor usage was demon-
trated further by GH-1(V3ROD) in which only the V3 loop
as derived from ROD in the background of GH-1. This
himeric virus infected parental HeLa-CD4 and was in-
ibited by IVR7. To further map the subregion of the V3
oop that determines the coreceptor usage, we tested
wo chimeric viruses GH-1 (V3RG) and GH-1 (V3GR) in
hich the N-terminal half and the C-terminal half of the
3 loop were derived from ROD, respectively (Fig. 4).
hereas GH-1(V3RG) infected only CCR5-expressing
eLa-CD4 and was not inhibited by IVR7, GH-1(V3GR)
nfected parental HeLa-CD4 and was inhibited by IVR7.
hus the C-terminal half of the V3 loop region is critical,
t least in the context of gp120 of GH-1, in determining
FIG. 5. Coreceptor usage of the chimeric HIV-2 viruses. HeLa-CD4
ells stably transformed with LTR-b-gal were transiently transfected
ith a control or a CCR5-expression vector and infected with indicated
iruses. The treatment of cells with IVR-7, an monoclonal anti-CXCR4
Hori et al., 1998), or control mouse IgG was carried out for 1 h at 37°C
efore infection. After 4 days, transactivation of the LTR-b-gal reporter
ene was measured. All assays were done in triplicate and mean 6 SD
as obtained. Representative results from three separate experiments
re shown.he coreceptor usage between CCR5 and CXCR4.
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240 ISAKA ET AL.We also wished to examine the coreceptor usage of
he parental and chimeric GH-1 viruses by using natural
arget cells. However, even the parental ROD and espe-
ially GH-1 gew only poorly in PHA-activated PBMC. This
as probably due to their long-term adaptation to estab-
ished cell lines (Clavel et al., 1986; Hasegawa et al.,
989). We therefore infected these viruses to Jurkat and
olt-4 (Fig. 1). As shown in Fig. 6, infection of ROD to
urkat was effectively blocked by SDF-1 but not by RAN-
ES, whereas that of GH-1 to Molt-4 was inhibited by
ANTES but not by SDF-1. The relative inefficiency of
ANTES in inhibiting infection of GH-1 to Molt-4 might be
ue to its utilization of multiple coreceptors expressed on
olt-4. Among the chimeric viruses, only V3ROD and
3GR, both of which were capable of using CXCR4 but
ot CCR5 (Fig. 4), grew well in Jurkat and Molt-4. As
xpected, their infections were effectively blocked by
DF-1 but not by RANTES. Thus these results were
onsistent to those obtained by using HeLa-CD4 trans-
ectants and supported in part the important role of the
-terminal half of the V3-loop region in the coreceptor
sage even using natural T cell lines.
In Fig. 7, the amino acid alignment of the V3 loop
egions of ROD, GH-1, and two V3-loop chimeric viruses
FIG. 6. Inhibition of infection of the parental and chimeric HIV-2 viruse
ith ROD, GH-1, and indicated chimeric viruses. In some cultures, RANT
etermined at indicated days postinfection. All assays were done in
eparate experiments are shown.s shown. Furthermore HIV-2 and SIV clones with known Coreceptor usage are shown for comparison (Deng et al.,
997; Hill et al., 1997; McKnight et al., 1998). In compar-
son to ROD, GH-1 has six amino acid differences (posi-
ions 8, 10, 11, 13, 18, and 29) and two amino acid
eletions (position 23 and 24). The C-terminal half of the
3 loop region that is critical in determining the corecep-
or usage corresponds to the sequence between aa-18
nd aa-36. In this region, histidine at position 18 and
ysine at position 29 in ROD are substituted by leucine
nd threonine, respectively, in GH-1 and histidine and
yrosine at positions 23 and 24 are absent in GH-1. The
wo amino acid substitutions at positions 18 and 29 as
ell as the deletion at position 23 all result in decrease
n the net positive charge. A similar correlation between
he coreceptor usage and the net charge of the V3 loop
s seen among other HIV-2 and SIV clones. This obser-
ation is also consistent to the reported correlation be-
ween the coreceptor usage and the net charge of the V3
oop region in HIV-1 strains (Shioda et al., 1992). Further-
ore the N-terminal half (aa-1 to aa-17) of UC2 is iden-
ical to that of GH-1 even though UC2 uses CXCR4. This
s quite in keeping with the present observation that the
-terminal half (aa-18 to aa-36) of the V3 loop is critical
or determining the coreceptor usage between CCR5 and
man T cell lines by SDF-1 or RANTES. Jurkat and Molt-4 were infected
DF-1 was included at 5 mg/ml. RT activity in culture supernatants was
te and mean 6 SD was obtained. Representative results from threes to hu
ES or S
triplicaXCR4. The net charge differences between the X4 and
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241ROLE OF V3 LOOP IN CORECEPTOR USAGE OF HIV-25 clones are also more pronounced when their C-
erminal halves are compared. It is also notable that the
wo X4 clones have histidine at aa-18, whereas all the R5
lones have leucine at this position.
In conclusion, HIV-2 GH-1, despite its isolation from an
IDS patient in Ghana and its long-term adaptation to
stablished cell lines, uses mainly if not exclusively
CR5 as the entry coreceptor instead of CXCR4. Further-
ore GH-1 is unable to use CCR1, CCR2b, or CCR3 even
hough R5 strains of HIV-2 are usually highly promiscu-
us and able to use, apart from CCR5, one or more of the
CR1, CCR2b, and CCR3 (Morner et al., 1999). It is not
nown whether GH-1 clone with such a restricted core-
eptor usage was representative of the viral quasispe-
ies in the original patient. Nevertheless, the availability
f two HIV-2 molecular clones GH-1 and ROD with dis-
inct coreceptor usage allowed us for the first time to
ap the region of gp120 of HIV-2 that critically deter-
ines the coreceptor usage. Like that of HIV-1, the V3
oop region of gp120 of HIV-2 has been shown to be
ritical for the coreceptor usage and only a few amino
cid changes especially in the C-terminal half of this
egion dramatically shift the coreceptor usage between
CR5 and CXCR4. The availability of GH-1, ROD, and
heir chimeric molecular clones thus may be useful to
urther analyze the interaction of HIV-2 gp120 proteins,
hich tend to be less dependent on CD4 and more
tructurally stable than those of HIV-1 (Ross et al., 1999),
ith CD4 and an entry coreceptor.
MATERIALS AND METHODS
ells and chemokines
SW480 (Adachi et al., 1986) and HeLa-CD4 cells stably
ransfected with a LTR-b-gal reporter gene [HIV-1 NL432
ong terminal repeat (LTR)-b-galactosidase] (Tachibana
FIG. 7. Amino acid alignment of the V3 loop regions of HIV-2 and SI
hown on the right.t al., 1997) were maintained in DMEM (GIBCO–BRL) gupplemented with 10% heat-inactivated fetal calf serum
FCS). CD4-positive human cell lines M8166, Jurkat, and
olt-4 (Shibata et al., 1990; Kawamura et al., 1998) were
aintained in RPMI 1640 supplemented with 10% heat-
nactivated FCS. Recombinant chemokines were pur-
hased from Peprotech.
iruses
The following molecular infectious clones were used;
NL432 for HIV-1 NL432 (Adachi et al., 1986), pNL162env
or HIV-1 NL162 (Tachibana et al., 1997), pGH-123 for
IV-2 GH-1 (Shibata et al., 1990), and pLA317 for HIV-2
OD (Kawamura et al., 1998). Six GH-1 clones with the
egion of gp120 chimeric between ROD and GH-1 were
enerated as follows. The full-length coding region of
IV-2 ROD gp120 was amplified from pLA317 by using
rimers 159-CATTTTGCTAGCTAGTGCTTGCTTAGTA and
59-CTGCTGTCGCGAGAAAACCCAAGAACCC and li-
ated to the NheI and NruI sites of pGH123 to generate
H-1(RODNN). The N-terminal half of HIV-2 ROD gp120
ncluding the V3 loop was amplified from pLA317 by
sing primers 159-CATTTTGCTAGCTAGTGCTTGCTTA-
TA and 259-TGCTTGCCTAGGTCTTTTATTGATCGGCTG
nd ligated to the NheI and AvrII sites of pGH123 to
enerate GH-1(RODNA). The C-terminal half of HIV-2
OD gp120 without the V3 loop was amplified from
LA317 by using primers 159-AAAAGACCTAGGCAAG-
ATGGTGCTGGTTCAAA and 259-CTGCTGTCGCGAGA-
AACCCAAGAACCC and ligated to the AvrII and NruI
ites of pGH123 to generate GH-1(RODAN). The V3 loop
egion of HIV-2 ROD was synthesized and ligated to the
maI site (created by PCR subcloning) and AvrII site of
GH123 to generate GH-1(V3ROD). The N-terminal half of
he V3 loop region of HIV-2 ROD was synthesized and
igated to the SmaI and BalI/StuI sites of pGH123 to
s. A gap is indicated by 2.The net charge and coreceptor usage areV cloneenerate GH-1(V3RG). The C-terminal half of the V3 loop
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242 ISAKA ET AL.egion of HIV-2 ROD was synthesized and ligated to the
alI/StuI and AvrII sites of pGH123 to generate GH-
(V3GR). SW480 cells were transfected with the plasmids
y modified calcium phosphate method (Adachi et al.,
986) and cultured for 48–72 h. The culture supernatants
ere then used to infect M8166. The culture superna-
ants were harvested after the appearance of cytopathic
ffects, clarified by centrifugation at 3000 rpm for 15 min
t 4°C, and stored in aliquots as virus stocks at 280°C
ntil use.
nfectious assay
HeLa-CD4 cells stably transfected with an LTR-b-gal
eporter gene were seeded into 6-cm dishes at 2 3 106
ells per dish. After overnight culture, cells were trans-
ected with 20 mg of an expression vector for CCR1,
CR2b, CCR3, or CCR5 (Kitaura et al., 1996; Tachibana et
l., 1997) by using a modified calcium phosphate method
Adachi et al., 1986). After 48 h culture, cells were
ashed with PBS, resuspended by using PBS containing
.5 mM EDTA, and seeded into 24-well plates. Cells were
nfected with virus in 500 ml of culture medium (RT
ctivity, 1 3 106 cpm/ml) for 2 h at 37°C and supplied
ith 2 ml of culture medium. After 4 d, cells were lyzed by
reezing and thawing in 250 ml of the reporter lysis buffer
Promega). After centrifugation, each sample was as-
ayed in triplicate by using Luminescent b-gal Detection
it (CLONTECH). To determine the role of endogenous
XCR4, cells were pretreated with a mAb IVR7 (Hori et
l., 1998) or control mouse IgG at 500 mg/ml for 1 h at
7°C and infected with the virus. To determine HIV rep-
ication in T cell lines, 2 3 105 cells of Molt-4 or Jurkat
ere mixed with 1 ml of HIV-2 GH-1 (RT activity, 1 3 106
pm/ml), ROD (RT activity, 0.5 3 106 cpm/ml), or chimeric
iruses (RT activity, 2 3 106 cpm/ml). After incubation at
7°C for 1 h, cells were washed, seeded into 96-well
lates (2 3 104 cells/well) and cultured at 37°C in 5% CO2
ir. In some cultures, chemokines were included at 5
g/ml. After 3, 5, and 7 d p.i., RT activities in the culture
upernatants were determined as described previously
Sato et al., 1995).
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